A retrospective exploratory study published in Cureus on October 31, 2026 compares hydrocortisone and dexamethasone when treatment begins in the second week after birth in premature infants considered at risk of bronchopulmonary dysplasia. The paper, titled "Hydrocortisone Versus Dexamethasone Initiated in the Second Postnatal Week in Preterm Neonates at Risk of Bronchopulmonary Dysplasia: A Retrospective Exploratory Comparative Study," was reported by Cureus.
According to Cureus, the work is a comparative look at two steroid options in this group of newborns. The study design is retrospective, meaning it examines care that has already taken place rather than assigning infants to a treatment in advance, and Cureus labels it exploratory.
Bronchopulmonary dysplasia is a chronic lung condition that can affect babies born prematurely, and steroid treatment is one area clinicians have studied in efforts to reduce that risk. The timing of when therapy starts is central to this paper, which focuses specifically on the second postnatal week.
The available summary of the Cureus report does not include patient numbers, outcomes, or findings, so no conclusions about which drug performed better can be drawn from it. The publication's title and summary describe the scope and design of the comparison only.
Because the study is retrospective and exploratory, its results would generally be viewed as a starting point rather than definitive guidance. Readers should watch for the full Cureus article, which would carry the detailed methods and results needed to assess how the two drugs compared.
